Zai Lab (ZLAB) Non-Current Deffered Revenue (2016 - 2026)
Zai Lab (ZLAB) posted Non-Current Deffered Revenue of $28.6 million for Q1 2026, up 4.73% sequentially from $27.3 million in Q4 2025, and down 4.98% YoY from $30.1 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Non-Current Deffered Revenue (2016 - 2026) Analysis & Trends
Zai Lab has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $28.6 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 4.98% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (down 4.98% YoY) and the FY2025 annual result came in at $27.3 million, down 13.04% from the prior year.
- Non-Current Deffered Revenue advanced to $28.6 million in Q1 2026 per ZLAB's latest filing, from $27.3 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $31.4 million in Q4 2024 and troughed at $21.4 million in Q4 2022.
- A 5-year average of $27.3 million and a median of $27.9 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue fell 22.29% in 2022, then jumped 34.54% in 2023.
- Over 5 years, Non-Current Deffered Revenue stood at $21.4 million in 2022, then surged by 34.54% to $28.7 million in 2023, then climbed by 9.38% to $31.4 million in 2024, then dropped by 13.04% to $27.3 million in 2025, then increased by 4.73% to $28.6 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $28.6 million, $27.3 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Zai Lab | 2.92 Bn | 2.21 Bn | 58.15 Mn | 27.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.50 Mn |
| Mar 31, 2026 | 28.63 Mn |
| Dec 31, 2025 | 27.33 Mn |
| Sep 30, 2025 | 28.06 Mn |
| Jun 30, 2025 | 29.23 Mn |
| Mar 31, 2025 | 30.13 Mn |
| Dec 31, 2024 | 31.43 Mn |
| Sep 30, 2024 | 24.92 Mn |
| Jun 30, 2024 | 25.34 Mn |
| Mar 31, 2024 | 26.30 Mn |
| Dec 31, 2023 | 28.74 Mn |
| Sep 30, 2023 | 27.69 Mn |
| Jun 30, 2023 | 28.63 Mn |
| Mar 31, 2023 | 30.97 Mn |
| Dec 31, 2022 | 21.36 Mn |
| Sep 30, 2022 | 23.21 Mn |
| Jun 30, 2022 | 24.78 Mn |
| Dec 31, 2021 | 27.49 Mn |
| Dec 31, 2017 | 2.39 Mn |
| Dec 31, 2016 | 778,434.00 |